clara.vrx.palo-alto.ca.us
Articles | Design | Editor | WORKS| Bespoke web
Photoessays | INU AI| Pumpkin
Illness | Language |ESSIAC| Cartierism | Health | Selenium | Reference | Niacin | Addiction | Diet | Diabetes | Healthy food | Arctic | News | Canada | NIHB
Salvestrol | Rene caisse | Abiraterone acetate
Essiac and Salvestrol - Cancer
Essiac and Salvestrol - Cancer

Cranberries contain salvestrols and are so harvested to make the Salvestrol treatment. The sister drug of salvestrols, Abiraterone Acetate, is now offered at no charge for many residents of Canada from the government.



A pharmaceutical researcher in Leicester England named Gerry Potter researching Cytochrome enzyme pathway drugs discovered two anti cancer drugs in the early 21st century. The first, he created and works only on prostate cancer. Because it's synthetic it's eligible for patent rights. It's based on the CYP 17 variant of Cytochrome P450 enzyme family and is called Abiraterone Acetate. [1][2].


He then found by accident tangerine peel contained the CYP1B1 variant as a bitter component of the peel, and it works on all cancers, but because it's not eligible for patent not being synthetic, there is zero commercial interest in it. This is Salvestrol which in my opinion should be called vitamin F, it pretty much does to cancer what vitamin C does to scurvy. [3]

"An intriguing strategy for treating cancer is the design of prodrugs for specific activation by cytochromes P450 (CYPs) that are highly overexpressed in cancer cells, such as CYP1B1 (Murray et al 1997; Potter et al 2002a).In our laboratories this work has led to the discovery that the well-known dietary anticancer phytochemical, resveratrol, is metabolised by CYP1B1 in vitro cytotoxic derivatives (Potter et al 2002b). Recently we have discovered several further natural dietary phytochemicals that are specifically activated into cytotoxic metabolites by CYPs overexpressed in cancer cells. These phytochemicals comprise diverse chemical types and have been given the collective name,Salvestrols. "[4]

Cyp17
[1] web.archive.org/web/20120608201500/http://www.sfgate.com/cgi-bin/article.cgi?f=%2Fc%2Fa%2F2012%2F06%2F02%2FMNI11ORI84.DTL
Cyp 1B1
[2] news.bbc.co.uk/2/hi/health/6987200.stm
Reservetrol [
3] nature.com/bjc/journal/v86/n5/abs/6600197a.html
Salvestrols
[4] readcube.com/articles/10.1211%2F002235707781850122
Tangerine peel
[5] web.archive.org/web/20120515074933/http://www.drshen.com/citrusherb
[6] web.archive.org/web/20120320233458/http://www.drshen.com/chineseherbsforcancer
[7] onlinelibrary.wiley.com/doi/10.1111/j.1541-4337.2012.00201.x/pdf

Summarized here by one of the team that discovered it:
(Short, 11 mins)
https://www.youtube.com/watch?v=XzuHbmhTYWQ
Long (90 mins)
https://www.youtube.com/watch?v=J4tpPlqMJ7Y

ABIRATERONE ACETATE
Limited use benefit (prior approval required). Initial coverage criteria (Initial approval for 12 months) For the treatment of metastatic castration resistant prostate cancer patients (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT) and who have not received prior chemotherapy if they meet the following criteria:
Used in combination with prednisone; AND Patient has an ECOG performance status of 0 or 1. For the treatment of metastatic castration resistant prostate cancer patients (mCRPC) who progressed on docetaxelbased chemotherapy if they meet the following criteria:
Used in combination with prednisone; AND Patient has an ECOG performance status ≤ 2; AND Abiraterone is not used as an add-on therapy to enzalutamide (Xtandi); AND Abiraterone has not been used in the pre-docetaxel setting.
Renewal coverage criteria (Renewal for 12 months)
There is no objective evidence of disease progression
250MG TABLET 02371065 ZYTIGA JSO
500MG TABLET 02457113 ZYTIGA JSO
More on Abiraterone Acetate

NIHB Drug Benefit List PDF
Ontario Drug Benefit

abiraterone_acetate-01t.jpg
abiraterone_acetate-01.jpg
xs sm lg
Remember me, buy my shirts!
pop art
MBZ